Sunday, March 12, 2017 4:46:14 PM
Accumulated a position in PGUZ (mostly at .004/shr) over the last few months. Definitely a high-risk investment for a number/variety of reasons, but the risk/reward around this price level looks intriguing. There has been some interesting activity on websites during 2016 that may have direct/indirect connections to products or technologies that have been associated with PGUZ.
One thing I would like the CEO to do is provide a very clear/detailed picture of PGUZ's current relationship/connection to the primary product/technology areas it is (or has been) involved with (anti-fungal products and the cardiac screening device/tech). That includes ownership rights, transfers of ownership, any licensing deals entered into, distribution deals, joint ventures, equity positions that PGUZ may have received from currently private companies, etc., etc. The reason I would like to see this type of clarification is because Google searches on the company and its technologies leads to a somewhat confusing/conflicting picture.
For example: It appears fairly clear that VE Science Technologies has some involvement in PGUZ's cardiac screening product/technology. I'm not sure whether it is because that company now owns the tech or whether it is from some type of licensing/distribution/marketing deal with PGUZ. In February 2016, VE Science sold the product distribution rights to Odyssey Group International......
http://www.cardiomap.com/
http://theodysseygroupinternational.com/?page_id=65
Despite all the confusion and risks involved, I decided to take a position because if PGUZ does still maintain significant business/financial interests in the above product areas this stock could have some explosive potential based on some of the updates of websites related to the anti-fungal product(s).
To the best of my knowledge, it has never been publicly-disclosed before that large pharma/biotechs like Amgen and Celgene have been using PGUZ's anti-mold product (MoldGuardian)......
http://www.moldguardian.com/about---pharma----biotech.html
http://contaminationprevention.com/pharmaceutical-biotech-solutionss/
PGUZ could generate some attention as a cannabis-related play (in the area of mold prevention). Last week's disclosure of mold contamination of samples taken from the federal government's marijuana facility might focus some investor interest in this area......
http://new.contaminationprevention.com/agricultural_contamination-prevention/
http://contaminationprevention.com/cannabis-mold-prevention/
http://www.pbs.org/newshour/updates/scientists-say-governments-pot-farm-moldy-samples-no-guidelines/
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM